ArticleOncoTargets and therapy2021

Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation.

Xiaomeng Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.